Skip to main content
EMV CAPITAL PLC logo

EMV CAPITAL PLC — Investor Relations & Filings

Ticker · EMVC ISIN · GB00BN4R5Q82 LEI · 213800N5WD46G1Y7I458 IL Financial and insurance activities
Filings indexed 547 across all filing types
Latest filing 2020-11-11 Regulatory Filings
Country GB United Kingdom
Listing IL EMVC

About EMV CAPITAL PLC

https://www.emvcapital.com/

EMV Capital PLC is a venture capital investment group specializing in deep tech and life sciences. The firm identifies, invests in, and builds high-growth, IP-rich companies with an international portfolio, focusing on sectors including industrial technology, healthcare, and sustainability. It employs a capital-efficient investment strategy that combines syndicated investments, direct balance sheet funding, and managed funds to support companies from their early stages through to successful exit. EMV Capital engages in proactive portfolio management, often taking board positions and working closely with company leadership. It provides extensive value creation services, including support for fundraising, exit readiness, IP strategy, and corporate collaborations, to drive growth and maximize returns for investors through strategic exits.

Recent filings

Filing Released Lang Actions
PDS updates on Versamune based COVID-19 vaccine
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces a business update regarding a portfolio company's (PDS Biotechnology) vaccine development progress. Since it is a general regulatory announcement that does not fit into specific categories like financial reports, M&A, or dividends, it falls under the RNS (Regulatory Filings) category.
2020-11-11 English
PDS Biotech Initiates VERSATILE-002 Phase 2 Trial
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement issued by NetScientific PLC regarding a clinical trial update from its portfolio company, PDS Biotechnology. It functions as a corporate press release announcing operational progress (the initiation of a Phase 2 clinical trial). Since it does not fit into specific categories like financial reports, board changes, or dividend notices, and is a standard regulatory announcement disseminated via the London Stock Exchange's RNS platform, it is classified as a Regulatory Filing.
2020-11-10 English
PDS Announces Initiation of PDS0101 Phase 2 Trial
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement issued by NetScientific PLC regarding a portfolio company's clinical trial progress. It functions as a general corporate update and regulatory disclosure of inside information. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the RNS fallback category.
2020-10-27 English
NetScientific acquires 100% of portfolio company
M&A Activity Classification · 100% confidence The document is an official announcement from NetScientific PLC regarding the acquisition of the remaining 43.6% stake in its portfolio company, ProAxsis Limited. This constitutes a corporate transaction involving M&A activity. The document details the consideration paid, the strategic rationale, and the financial impact on the parent company. It is distributed via the London Stock Exchange's RNS (Regulatory News Service), which is standard for such announcements.
2020-10-16 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for the fiscal year 2019, including a balance sheet ('Bilanz') and notes ('Anhang') prepared under the German Commercial Code (HGB). It provides comprehensive financial data for the year rather than just an announcement or a summary. Given the definition of '10-K' as an official yearly report covering company activity and full financial performance, this document fits the criteria for an Annual Report. FY 2019
2020-10-12 German
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification regarding transactions by a person discharging managerial responsibilities (PDMR), specifically Dr. Ilian Iliev, a Director of NetScientific plc. It follows the standard regulatory format for reporting director dealings, including the name of the person, their position, the nature of the transaction (share issuance/acquisition), the price, and the volume. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2020-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.